back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-03-13 14:08 Tx date 2024-03-07 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$666.70
+6,667 vol $0.10 each |
30,889 | |
| Filed 2024-03-13 14:06 Tx date 2024-03-07 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
57 - Exercise of rights
|
-6,667 vol |
213,333 | |
| Filed 2024-01-02 16:58 Tx date 2023-12-29 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
$2,695
+24,222 vol $0.1113 each |
24,222 | |
| Filed 2024-01-02 16:57 Tx date 2023-02-21 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-11-30 17:15 Tx date 2023-11-28 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+200,000 vol |
220,000 | |
| Filed 2023-10-11 14:00 Tx date 2023-10-10 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Warrants
11 - Acquisition or disposition carried out privately
|
+476,200 vol |
476,200 | |
| Filed 2023-10-11 13:58 Tx date 2023-02-21 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-10-11 13:57 Tx date 2023-10-10 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures 12% Unsecured Convertible Debenture
11 - Acquisition or disposition carried out privately
|
$
+$100 vol $1,000 each |
$100 | |
| Filed 2023-10-11 13:56 Tx date 2023-02-21 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures 12% Unsecured Convertible Debenture
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-03-10 16:20 Tx date 2023-03-08 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+20,000 vol |
20,000 | |
| Filed 2023-03-10 16:00 Tx date 2023-02-21 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-03-10 15:58 Tx date 2023-03-08 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
200,000 | |
| Filed 2023-03-10 15:52 Tx date 2023-02-21 |
$WLLW
Willow Biosciences Inc. |
Lalonde, James Joseph
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|